ReviewHealth research policy and systems2025
Driving health transformation: big pharma's innovation labs revolution.
Review in Health research policy and systems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinician Participation in Innovation Labs at University Hospitals: Mixed Methods Study.Journal of medical Internet research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundLarge pharmaceutical companies are evolving their innovation strategies, moving from closed R&D models towards open, collaborative ecosystems. Innovation labs have emerged as key organizational infrastructures in this shift, designed to accelerate the development, validation and adoption of new healthcare solutions. However, a systematic understanding of industry-led innovation labs remains limited.
objectiveThis study aims to comprehensively characterize the structure, strategic focus, activities and outputs of innovation labs promoted by major pharmaceutical companies, and to identify patterns and divergences across different organizational models.
methodsWe conducted a structured literature review in PubMed and an original mapping of innovation labs established by the top 20 global pharmaceutical companies. Data were collected from peer-reviewed publications, official corporate reports and grey literature. Innovation labs were analyzed according to their digital orientation, geographical structure (unicentric versus multicentric), activity domains, stakeholder engagement and innovation outputs.
resultsA total of 102 innovation centres promoted by 14 pharmaceutical companies were included. Most centres demonstrated a strong digital focus, particularly on digital health solutions and remote patient monitoring. Collaboration activities were widely reported (98%), mainly involving universities (92%) and other industries (65%). Support for entrepreneurship was a major theme, reflected in mentoring programs (87%), co-development opportunities (85%) and access to funding (40%). A comparative analysis revealed that multicentric initiatives were significantly more engaged in external collaborations, entrepreneurship promotion and educational activities, and produced higher rates of patents and spin-offs compared with unicentric initiatives. However, unicentric labs were more associated with internal capacity building and early-stage clinical research.
conclusionsPharmaceutical innovation labs are pivotal in healthcare transformation, integrating scientific, technological and entrepreneurial approaches. Multicentric and unicentric models offer complementary strengths: multicentric hubs enhance external engagement and scalability, while unicentric labs foster organizational learning and focused research. Understanding and strategically balancing both models could maximize the impact of pharmaceutical innovation infrastructures. Future research should explore longitudinal impacts, patient involvement and the interaction of innovation labs with venture capital ecosystems and regulatory frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.